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ABSTRACT 
Background and aims. Familial hypercholesterolemia (FH) is a genetic disorder characterized 
by high levels of low density lipoprotein cholesterol (LDL-C) predisposing to premature 
cardiovascular disease. Its prevalence varies and has been estimated around 1 in 200-500. 
The Heredity survey evaluated the prevalence of potential FH and the therapeutic approaches 
among patients with established coronary artery disease (CAD) or peripheral artery disease 
(PAD) in which it is less well documented.  
Methods. Data were collected in patients admitted to programs of rehabilitation and secondary 
prevention in Italy. Potential FH were estimated using Dutch Lipid Clinic Network (DLCN) 
criteria. Potential FH were defined as having a total score ≥6. 
Results. Among the 1438 consecutive patients evaluated, the prevalence of potential FH was 
3.7% . The prevalence was inversely related to age, with a putative prevalence of 1:10 in 
those with <55yrs of age (male) and <60yrs (female). Definite FH (DLCN score >8) had the 
highest percentages of patients after an ACS (75% vs 52.5% in the whole study population). 
At discharge, most patients were on high intensity statin therapy, but despite this, potential FH 
group still had a higher percentages of patients with LDL-C levels not at target and having a 
distance from the target higher than 50%.  
Conclusions. Among patients with established coronary heart disease, the prevalence of 
potential FH is higher than in the general population; the results suggest that a correct 
identification of potential FH, especially in younger patients, may help to better manage their 
high cardiovascular risk. 
 
KEYWORDS: familial hypercholesterolemia; coronary artery disease; lower extremities 
peripheral disease; prevalence; statins. 
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INTRODUCTION 
Familial hypercholesterolemia (FH) is a genetic-based disease characterized by premature 
atherosclerotic disease due to the presence of high low density lipoprotein cholesterol (LDL-C) 
levels from birth
1-3
. Mutations in the gene encoding the receptor for LDL (LDLR) are the most 
common cause of FH, but mutations in other genes involved in LDL metabolism, including 
proprotein convertase subtilisin/kexin type 9 (PCSK9) and apolipoprotein B, may lead to 
similar phenotypes4. In the general population, the frequency of homozygous FH, requiring 
therapeutic intervention in the first decade of life, is very low (1:1,000,000)2, 4. On the 
contrary, heterozygous FH in Caucasians is more common; historically, its prevalence was 
estimated at 1 in 500, but more recent studies suggest a higher frequency, up to 1 in 200-
2505. Because of the exposure to high levels of LDL-C from birth (200-400 mg/dL; 5-10 
mmol/L), FH subjects have a significantly greater risk of cardiovascular disease and, if 
untreated, they may experience cardiovascular events early in the life6. Thus, the identification 
of FH subjects is critical for the prevention of coronary heart disease through early and 
effective therapeutic approaches. Despite this, the identification of patients with heterozygous 
FH is still partial in Europe, in particular in Italy2.  
Different criteria have been proposed to allow the detection of FH patients, including the Simon 
Broome Register Diagnostic criteria7, the MedPed/WHO criteria8 and the Dutch Lipid Clinic 
Network (DLCN) Diagnostic criteria9. These algorithms are mainly based on the blood LDL-C 
levels, a positive family history of coronary artery disease (CAD), personal CAD history and 
physical signs7-9.  
Recently, it was shown that among patients with CAD or other atherosclerotic diseases the 
frequency of FH is significantly higher than in general population and that these patients are at 
particularly elevated risk of recurrent events10-12. In particular, the post hoc analysis of 
EUROASPIRE IV reported an increased prevalence of potential FH in coronary patients from 24 
European countries by means of standardized interview and biochemical and clinical 
examination using an adapted version of the DLCN criteria10. However, this study did not 
include Italian patients; to overcome this lack, we designed the “HEterozigous familial 
hypeRcholesterolemia in patiEnts admitted to carDiac rehabilitaTion programs in Italy” 
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(HEREDITY) survey through Italy’s national network of cardiac rehabilitation and secondary 
prevention (CRP) centres. This survey aimed at investigating the prevalence of heterozygous 
FH using the DLCN criteria among “real world” patients with CAD or peripheral artery disease 
(PAD) admitted to programs of rehabilitation and secondary prevention. Potential FH patients, 
defined as having a Dutch score ≥6, were compared with the other patients and evaluated at 
discharge. Moreover, this study evaluated the therapeutic approaches and the results obtained 
in terms of recommended lipid target values. 
 
METHODS 
Study design 
The HEREDITY survey was an observational multicentre nationwide survey involving 26 in- and 
out-patients CRP units. Each participating centre was asked to provide clinical and biochemical 
data of at least 50 consecutive patients discharged (between February and March 2015), in 
order to ensure the expected sample size (more than 1000 patients), after a CRP program (4-8 
weeks of duration) for recent (within 2 weeks) acute coronary syndrome (ACS) and/or 
percutaneous/ surgical myocardial revascularization or stable angina with medical therapy or 
for lower extremity PAD with or without recent acute event. 
Electronic case report forms (eCRF) were used for data entry, and data were transferred via 
web to a central database. Patients' anonymity was ensured. The eCRF were collected and data 
were analysed in relation to the characteristics of patients (sex, age, BMI), admission 
diagnosis, CRP setting (inpatients or outpatients), co-morbidities, global risk profile, drug 
therapy and biochemical parameters including total cholesterol, LDL-C, HDL-C, triglycerides 
(TG) and glycaemia values at discharge. Total cholesterol, HDL-C and TG were measured by 
local laboratories, all accredited by ISO 15189:2003 (Medical Laboratories- Particular 
requirement for quality and competence). LDL-C was calculated according to the Friedewald’s 
formula. The prevalence of FH was estimated using the DLCN criteria2 . 
Since a large majority of the patients (80.3%) was on statin therapy for at least four weeks at 
the moment of blood sampling at admission to CRP program, the LDL-C levels obtained were 
adjusted by correction factors taking into consideration the type and dose of statin11, 13. 
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The results of the algorithm were interpreted as follows: unlikely FH, total score 0-2; possible 
FH, total score 3-5; probable FH, total score 6-8; definite FH, total score>8. Potential FH were 
defined as having a total score ≥6. 
Local Ethical committees approved the study. All patients provided written informed consent. 
The survey involved no diagnostic tests, care interventions or pharmacological treatments that 
were not part of the routine clinical practice of each participating centre, and each physician 
enrolling a patient was fully responsible for his/her management. The survey was 
independently conducted and the data were analysed under the scrutiny of the Steering 
Committee of the study.  
 
Statistical methods 
We expected to enrol a total sample of approximately 1,000 patients. According to the 
literature data, we hypothesized a prevalence of heterozygous FH of approximately 5% in our 
study population, thus allowing to obtain a sample of about 50 patients with probable-definite 
FH. All data collected in the online database underwent data cleaning and quality control. 
Continuous variables were expressed as mean±standard deviation (SD) and median (range), 
categorical variables as number and percentage. Enrolled patients were analysed both as a 
whole population and by single FH probability class . Patients were also analysed by comparing 
the group of potential FH having a Dutch score ≥6 (probable FH+definite FH) with all the other 
patients (unlikely FH+possible FH). 
Differences between these groups were tested by the Fischer’s exact test or Chi Square 
(categorical data) and by Student’s t-test (continuous numeric data). All computations were 
carried out with SAS® statistical software (SAS Institute, Cary, NC, USA – version 9.2) and a 
p<0.05 was considered significant. 
 
RESULTS 
This survey included a total of 1438 patients recruited from 26 CRP centres (Appendix). Clinical 
characteristics of the patients participating in this study are presented in Table 1. Men were 
83.7% of the sample; mean age of the whole study population was 65.9±10.6 years, and more 
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than one fourth of total population (429 out of 1438, 29.8%) was ≤60 years old. Recent ACS, 
with or without percutaneous myocardial revascularization, was the most common clinical 
presentation (52.5%), followed by stable CAD on medical therapy (26.5%) and symptomatic 
chronic CAD undergoing surgical or percutaneous myocardial revascularization (18%); isolated 
lower extremity PAD was the least common presentation (3.1%) (Table 1).  
Table 2 reports the prevalence for the different categories of FH according to DLCN criteria by 
gender, age and entry diagnosis. Considering the whole population, 53 patients (3.7%) had a 
score ≥6 (potential FH) and 12 (0.8%) had a score>8 (definite FH). Patients with potential FH 
(probable+definite) were younger compared with the other group (unlikely/possible) 
(58.3y±11.5 vs 66.2±10.5, p<0.001) (Table 2). The younger population (i.e. men <55 years 
and women <60) had a significantly higher prevalence of potential FH compared with older 
patients (10.4% vs 2.3%, p<0.001) 
The prevalence of potential FH was higher in women (5.5%) than in men (3.3%); the analysis 
by age subgroups showed that this finding was valid in patients aged 50-69 years, while 
among patients aged <50 years or >70 years the prevalence was higher in men. Among 
potential FH patients, 30.2% had <50 years and 58.5% had <60 years, compared with 8% 
and 28.7%, respectively, among unlikely/possible FH patients. Among subjects aged <50 
years, 12.6% were potential FH but this percentage was drastically reduced in the other 
classes of age (51-60y: 5%; 61-70y: 2.7%; >70y: 1.6%, P<0.001). About half of the patients 
enrolled presented with an ACS with or without revascularization (52.5%); when analysed 
within the single groups, definite FH had the highest percentages of patients presenting with 
an ACS (75%) (Table 2). 
Considering the whole population, a higher number of patients was taking statins at discharge 
compared to the admission to CRP program (from 80.3% to 87.7%, p<0.001). The percentage 
of patients taking statin therapy was very high in probable FH (97.6% at discharge) and in 
definite FH (100%); in potential FH there was a 98.1% of patients taking statins, compared 
with to 87.3% in the unlikely/possible FH group.  
High intensity lipid-lowering approach (atorvastatin 40-80 mg, rosuvastatin 20-40 mg or 
simvastatin/ezetimibe combination) was used in 80.0% of whole population and in 92.2% of 
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potential FH patients. Atorvastatin (82.4%) and rosuvastatin (15.7%) were the most used 
statins in potential FH. None of the potential FH and very low percentage (2.4%) of 
unlikely/possible FH was discharged with low-intensity statin therapy. Also the use of ezetimibe 
therapy increased at the end of the survey (from 5.6% to 9.1%). The increase was more 
evident in probable FH (from 7.3% to 22.0%) and in definite FH groups (from 0% to 25%).  
At discharge, the percentages of patients with LDL-C levels at target (LDL-C<70 mg/dL) 
differed significantly among groups, being higher in the unlikely FH group (45.6%) and very 
low in the potential FH group (2.2%), due to the fact that only 1 patient of probable FH group 
and none of definite group had LDL-C levels at target (Figure 1). Among patients not at target, 
distance from target was higher than 50% in 2.8% of total population and in 36.6% of 
potential FH patients, despite high intensity therapy (Figure 2). When analyzed based on the 
distance from target, we observed that most patients were discharged with high-intensity 
statin therapy (80.9% of those with distance from target ≤50% and 76.7% of those with 
distance from target >50%), and only a minority was taking moderate-intensity statin therapy 
(Table 3) 
 
DISCUSSION 
The main finding of this study is to contribute, with Italian data, to the epidemiological 
evidence that FH condition may be highly probable within special groups of patients (such as 
those with cardiovascular disease) and to suggest a preferred context for the diagnosis of FH 
patients. In fact, we reported that, among patients with CAD and/or LE-PAD admitted to a 
structured program of CRP, the prevalence of FH is significantly higher than that observed in 
the general population, having found a 3.7% patients with a Dutch score ≥6 (potential FH) and 
0.8% with a Dutch score>8 (definite FH).  
Despite the numerical difference, this finding is in agreement with the observations reported in 
other recent studies10-12. In the EUROASPIRE IV survey, the prevalence of potential FH in 
coronary patients was 8.3%, while definite FH were 1.1%10, with large difference between 
countries. Our results on potential FH were very similar to those observed in South Europe 
countries (Spain 4.1%; Greece 3.8%; France 4.4%). These data, observed in post-acute phase 
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of coronary and peripheral artery disease, were different from those observed in the acute 
phase: in the study of Pang et al., the prevalence of potential FH in patients with early-onset 
coronary artery disease was 14.3% and definite FH was 2.3%11; Nanchen et al. reported a 
1.6% prevalence of potential FH among patients with acute coronary syndromes12. Altogether, 
these observations suggest that, although the prevalence of FH in the general population is 
relatively low, among patients with cardiovascular-related events this prevalence is several 
folds higher. 
In our survey, the prevalence of potential FH was inversely related to age, and more so in men 
that in women as observed also in other studies10, 12. This association with age may be 
explained by the weight given to younger age at the time of first CAD event in the DLCN 
criteria. The difference in the prevalence of potential FH by gender may partially be artificial 
due to the difference in defining premature CAD in men and women. It must be acknowledged, 
however, that the FH prevalence here reported cannot be compared to that of the general 
population, as in the sample selected for this survey (post-CAD/PAD patients) women and 
young people are obviously less represented. 
According to our data, more than 1 out of 10 patients younger than 55 years (male) or 60 
years (female) with previous atherosclerotic events is a potential FH, with obvious clinical 
implications for an adequate management. In fact, the higher prevalence of potential FH in 
patients with cardiovascular disease-related events, especially in those aged <55-60 years, 
opens the opportunity to increase the detection rate among family members. When a suspect 
case is detected, family screening protocols are warranted. All those identified with potential 
FH should receive high-intensity statins; even then, a large proportion will probably not reach 
the LDL-C goals recommended from international guidelines and combination therapies or new 
therapies should be considered in these patients.  
Furthermore, considering the different entry diagnoses recorded in our study population, a 
higher percentage of potential FH was observed among patients with a recent acute coronary 
syndrome compared with subjects with stable symptomatic CAD undergoing medical therapy 
or elective myocardial revascularization.  
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Another relevant finding of this study is that, both in the whole population and in the potential 
FH group, the percentage of patients under statin therapy increased significantly at discharge 
from cardiac rehabilitation program, compared with the admission, particularly those at high-
intensity statin therapy; it is worth noting that the therapeutic approach at discharge was 
driven by the incident cardiovascular event and not by the presence/absence of FH condition. 
Differently from data reported for other countries included in the Euroaspire IV study, the 
present study retrospectively showed that 92.2% of the patients with potential FH were on 
high-intensity statin therapy at discharge; despite that, only a minority of potential FH patients 
reached the desired LDL-C target <70 mg/dL, according to secondary prevention guideline 
recommendations, due to their higher baseline LDL-C levels. It is worth noting that, although 
the combination statin-ezetimibe has been established as an effective therapeutic approach for 
FH patients leading to an additional reduction of LDL-C levels of about 10-15% compared with 
statin alone14-16, in this study a very low number of patients received statin in combination 
with ezetimibe at discharge. This observation, together with the low proportion of patients 
reaching the recommended LDL-C levels suggested by their DLCN score established 
retrospectively (<70 mg/dL in the presence of CVD)17, suggests that, in the absence of a 
clinical evaluation of their possible FH condition, it may be difficult to set an appropriate 
pharmacological approach for these patients.  The SAFEHEART study, a large ongoing registry 
of molecularly defined patients with heterozygous FH treated in Spain, reported that, despite 
the use of intensified lipid-lowering therapies, many FH patients do not achieve the 
recommended LDL-C levels18. This suggests that, despite a genetic confirmation of their FH 
status, the most part of these subjects are not treated properly. 
 
Study limitations 
This study has several limitations: first, the lipid measurements were performed in different 
laboratories, although certified according to ISO rules; inter-laboratory variability may have 
conditioned the prevalence of potential FH; second, the DLCN questionnaires were frequently 
lacking for data on family and biochemical history, thus reducing the individual DLCN score and 
the probability to detect a potential FH case; third, most patients were on therapy at the time 
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of this evaluation, accordingly the “untreated LDL-C levels” were not measured but estimated 
using a correction formula based on literature data, although it was validated; and last, the 
survey was retrospective and genetic analysis was not performed in potential FH patients to 
confirm the diagnosis. In addition, in this survey, the diagnosis was performed through well 
established criteria, but genetic test was not performed. However we believe that the major 
issue is to detect patients with a high probability of having FH who are characterized by a very 
high cardiovascular risk and thus need an immediate and appropriate pharmacological 
approach to reduce the risk of secondary cardiovascular events. As also suggested by the 
results reported by the SAFEHEART registry18, the presence of a genetic confirmation of the FH 
status does not guarantee the management of these patients with proper pharmacological 
approaches and the subsequent attainments of LDL-C goals.  
 
Clinical implications 
The analysis of our data, extracted from a large population of patients with previous 
atherosclerosis-related cardiovascular events, indicates that potential FH is relatively common, 
especially in those 50 years old or younger and in those with a recent acute coronary 
syndrome. However, being patients suffering from peripheral artery disease only a marginal 
part of the evaluated population, we would not extrapolate our results to this subpopulation. 
We should also acknowledge that the results presented in this paper confirm the observations 
in other pathological populations and extend this finding also to the Italian population, and 
represent a further proof of the relevance of investigating the possible presence of FH patients 
within these groups. Accordingly, clinicians involved in care should have a high grade of 
suspicion in these patients and their families, for an early detection and treatment of this 
disease. Despite a large use of appropriate high-intensity lipid-lowering therapies, such as high 
dose statins and combination with ezetimibe, only a minority of treated patients usually reach 
the recommended targets of LDL-cholesterol (<70 mg/dL), thus emphasizing the need of 
appropriate pharmacological approaches, including high intensity statin and ezetimibe in 
combination. 
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TABLE 1. Characteristics of patients participating in the study. 
 Total patients 
N 1438  
Men 1203 83.7 % 
Women 235 16.3 % 
Mean age (y±sd)           Total 65.9±10.6  
Male 65.0±10.3 p<0.0001 
Female 70.2±10.9  
Setting   
Outpatients 750 52.2 % 
Inpatients 688 47.8 % 
Entry diagnosis    
LE-PAD 46 3.2 % 
Stable CAD  381 26.5 % 
Post-ACS 755 52.5 % 
PCI/CABG without ACS 259 18.0 % 
Co-morbidities:              No 490 34.1 % 
Yes 948 65.9 % 
Risk factors   
None 22 1.5 % 
Dislipidemia 1265 88.0 % 
Family history of CAD 549 38.2 % 
Hypertension 1010 70.2 % 
Diabetes 424 29.5 % 
Smoking 880 62.2 % 
Sedentary habits 670 46.6 % 
Obesity 368 25.6 % 
LE-PAD: lower extremity peripheral arterial disease; CAD: coronary artery disease; PCI/CABG: 
percutaneous coronary intervention/coronary artery bypass surgery; ACS: acute coronary 
syndrome 
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TABLE 2. Prevalence for the different categories of FH for all patients, by gender, age and entry diagnosis. 
 
 
FH classification  
 
Total 
patients 
Unlikely 
(DLCNS 0-
2) 
Possible 
DLCNS 3-5 
Probable 
DLCNS 6-8 
Definite 
DLCNS >8 
Potential 
DLCNS≥6 
 
Total 1438 
1070 
(74.4%) 
315 (21.9%) 41 (2.9%) 12 (0.8%) 53 (3.7%) 
 
Mean age 
(y±s.d.) 
65.9±10.6 68.0±9.5 59.9±11.1 60.1±11.9 52.1±7.9 58.3±11.5 
Analysis of variance 
(ANOVA)  
Men 1203 
886 
(73.6%) 
277 (23.0%) 30 (2.5%) 10 (0.8%)  40 (3.3 %) 
 
P<0.0442 
Women 235 
184 
(78.3%) 
38 (16.2%) 11 (4.7%) 2 (0.8%) 13 (5.5%) 
 
Age M<55; 
F<60  
250 99 (39.6%) 125 (50.0%) 17 (6.8%) 9 (3.6%) 26 (10.4%) 
 
P<0.0001 
Age M55; F60  1188 
971 
(81.7%) 
190 (16.0%) 24 (2.0%) 3 (0.3%) 27 (2.3%) 
 
LE-PAD 46 37 (80.4%) 7 (15.2%) 2 (4.3%) 0 (0.0%) 2 (4.3%) P=0.5773 
Stable CAD  
381 
283 
(74.3%) 
84 (22.1%) 12 (3.1%) 2 (0.5%) 14 (3.7%) 
P=0.8586 
Post-ACS 
755 
543 
(71.9%) 
178 (23.6%) 25 (3.3%) 9 (1.2%) 34 (4.5%) 
P=0.0754 
PCI/CABG 
without ACS 
259 
209 
(80.7%) 
47 (18.1%) 2 (0.8%) 1 (0.4%) 3 (1.2%) 
P=0.0256 
DLCNS: Dutch Lipid Network Criteria Score; LE-PAD: lower extremity peripheral arterial disease; CAD: coronary artery disease; ACS: acute 
coronary syndrome; M: male; F: female 
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Table 3. Intensity of statin therapy at discharge based on distance from target.  
 
 
 
Distance from target 
Statin intensity All patients ≤50% >50% 
 
N % N % N % 
Low intensity 20 1.9 20 2.0 - - 
Moderate intensity 178 17.3 171 17.1 7 23.3 
High intensity 832 80.8 809 80.9 23 76.7 
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Figure 1. LDL-C levels at discharge. See the text for details. 
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Figure 2. Distance from target, expressed as %. See the text for details. 
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APPENDIX. CRPs participating to the survey 
PARTECIPANT CENTERS AND INVESTIGATORS 
Dipartimento Scienze Farmacologiche e 
Biomolecolari and IRCCS Multimedica 
Milano 
Alberico L. Catapano 
Centro per lo Studio dell’Aterosclerosi, E. 
Bassini Hospital, Cinisello Balsamo, Milan 
Angela Pirillo 
Cardiologia Ospedale di Cremona Silvia Frattini 
Cardiologia Ospedale Fatebenefratelli 
Isola Tiberina, Roma 
Matteo Ruzzolini 
Cardiologia Riabilitativa - Azienda 
Ospedaliera Brotzu – Cagliari 
Andrea Bianco 
Cardiologia Riabilitativa Alta 
Specializzazione Motta di Livenza 
Giuseppe Favretto 
Cardiologia Riabilitativa Ospedale 
Niguarda, Milano 
Salvo Riccobono 
Cardiologia Riabilitativa Ponte dell'Olio, 
UOC Cardiologia Piacenza 
Giovanni Villani 
Cardiologia Spedali Civili Brescia Pompilio Faggiano, Luca 
Branca 
Centro Riabilitazione Cardiologica 
Ospedale S.Anna Castelnovo nè Monti - 
Reggio Emilia 
Gianni Zobbi 
FSM Cardiologia, Istituto di Cassano delle 
Murge, Bari 
Andrea Passantino 
FSM Cardiologia, Istituto di Milano Maurizio Bussotti 
FSM Cardiologia, Istituto di Veruno, 
Novara 
Pierluigi Temporelli 
FSM Cardiologia, Istituto di Pavia Roberto Pedretti 
Humanitas Gavazzeni, Bergamo Bruno Passaretti 
Istituto Auxologico Italiano, Milano Gabriella Malfatto 
FSM Cardiologia, Istituto di Montescano, 
Pavia 
Mariateresa La Rovere 
Cardiologia Ospedale di Noale, Venezia Franco Giada 
Ospedale Buccheri La Ferla 
Fatebenefratelli Palermo 
Filippo Sarullo 
Ospedale San Giovanni-Addolorata, Roma Gianfrancesco Mureddu 
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